Effect of Shufeiya Prescription on Pulmonary Artery Systolic Pressure and Quality of Life in Patients with Pulmonary Hypertension

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

暂无简介。

•1.Aged 18 to 80 years, gender is not limited;
•2.Meets the diagnostic standard of pulmonary hypertension;
•3.Patients with fixed dose and type of conventional medicine last month;
•4.Patients who did not receive targeted drug therapy or targeted drug therapy regimen fixed for at least a month;
•5.Patients who had not received interventional or surgical treatment within 6 months before the trial;
•6.Volunteer to participate in the clinical trial, understand and sign the informed consent.

•1.Patients with acute exacerbation of chronic heart failure, acute myocardial infarction, coronary revascularization, and cardiac resynchronization within a month before the trial;
•2.Patients with acute exacerbation of COPD/combined pulmonary infection within a month before the trial;
•3.Patients with right ventricular outflow tract obstruction;
•4.Patients with malignant tumors, mental disorders, malignant arrhythmias and other serious diseases;
•5.Patients with severe renal disease (serum creatinine > 450umol/L) or liver disease (including serum transaminase >3 times the upper limit of normal value);
•6.Patients who had taken Chinese medicine preparations (including TCM decoction pieces, granules, Proprietary Chinese medicine, TCM intravenous preparations, etc.) within 2 weeks before the trial;
•7.Patients with disadvantageous activities of lower limbs and unable to cooperate with the completion of relevant examinations;
•8.Pregnant women and lactating women;
•9.Patients with known allergy to the drug ingredients and excipients in this trial.

发起方